A most-wanted fugitive who vanished 20 years ago was just discovered working as chief medical officer of a NASDAQ-listed biotech. His fake résumé claimed Stanford, Harvard, and seven approved drugs. The real story exposes terrifying gaps in how the industry vets its leaders.
A Sailboat, a Fake Name, and a Corner Office
Federal agents boarded a 56-foot sailboat off the coast of New Jersey last week. They weren't looking for drugs or smuggled goods. They were looking for a man who had been on Rhode Island's most-wanted list for 20 years.
What they found was a 70-year-old former anesthesiologist named Ronald Fischer, who had vanished in April 2005 while on trial for first-degree sexual assault. He was later convicted in absentia. For two decades, Fischer lived under an alias: Richard Graydon.
And "Richard Graydon" wasn't hiding in a cabin somewhere. He was working as the chief medical officer of a publicly traded biotech company.
The Résumé That Should've Set Off Alarms
Immix Biopharma, a Los Angeles-based biotech listed on NASDAQ, hired "Dr. Richard Graydon" as its CMO in March 2026. The company issued a press release announcing the hire. It included a biography that would make any recruiter swoon.
According to that filing, Graydon held an MD and PhD from Stanford University. He trained at Harvard's Massachusetts General Hospital. He was a board-certified hematologist-oncologist. And he reportedly had more than 20 years of clinical development experience at Merck and Johnson & Johnson, with credit for helping bring seven approved drugs to market. We're talking KEYTRUDA, DARZALEX, CARVYKTI, IMBRUVICA.
That's not a résumé. That's a greatest-hits album. It's the biotech equivalent of someone claiming they played quarterback for three different Super Bowl winners.
The only problem? None of it appears to have been real. Or at least, none of it belonged to the man claiming it.
How Do You Hire a Fugitive?
This is the question keeping governance experts and investors up at night. A standard background check for a corporate hire typically involves criminal record searches, identity verification, education confirmation, and professional license validation. For a C-suite executive at a public company, the process is supposed to be even more rigorous: independent reference checks, regulatory-interaction references, sometimes reputational and adverse-media screening.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Somewhere in that chain, every single link failed.
If Immix's background check ran against the name "Richard Graydon," it wouldn't have flagged anything, because that person didn't have a criminal record. The criminal record belonged to Ronald Fischer. The gap between those two names is where due diligence went to die.
Proper primary source verification (calling Stanford directly, contacting Massachusetts General, checking with licensing boards) would presumably have revealed that no one named Richard Graydon earned those degrees or completed that training. But either those calls weren't made, or they were defeated by documentation Fischer had somehow obtained under his alias.
This wasn't a routine "failed background check" where a flag got missed. This was a complete breakdown in identity verification. Think of it like a bouncer checking a fake ID and waving someone into the VIP section of the FDA.
The Fallout Was Fast
Once the arrest hit the news, Immix moved quickly. In an SEC filing dated July 20, 2026, the company stated that Graydon had been terminated and was "no longer with the Company for reasons unrelated to his activities at the Company." Given his short tenure, management said they believed there would be "no material effect on the business."
The company's website scrubbed his photo and biography. But archived versions still showed everything: the headshot, the Stanford credentials, the pharmaceutical pedigree.
Wall Street wasn't reassured. Immix shares dropped roughly 14%, falling to $8.80 on July 20. Investors didn't care that Fischer's tenure was short. They cared that the company had apparently done so little to verify who it was putting in charge of clinical trials and regulatory submissions.
And honestly, can you blame them?
Why This Matters Beyond One Company
The chief medical officer isn't just another executive. The CMO oversees clinical trial design. They review safety data. They interact directly with the FDA. They sign off on regulatory submissions that determine whether drugs reach patients. Putting someone in that chair whose entire identity is fabricated doesn't just create a governance problem; it creates a potential patient safety crisis.
There's no evidence that Fischer's brief tenure caused direct harm to any clinical programs. But the principle is what makes this so alarming. If a most-wanted fugitive can bluff his way into the C-suite of a NASDAQ-listed biotech, what does that say about the systems we rely on to keep the industry honest?
The uncomfortable answer: those systems have gaps you could sail a 56-foot boat through.
A Pattern, Not an Anomaly
Biotech has seen its share of executive fraud in recent years. Keith Berman, CEO of Decision Diagnostics, got seven years in prison in 2024 for fabricating claims about a rapid COVID-19 test that didn't exist, bilking investors out of roughly $28 million. CytoDyn's former CEO Nader Pourhassan was convicted of securities fraud for lying about the regulatory timeline for an HIV drug, then selling stock at inflated prices.
But those cases involved known executives who lied about their products. The Fischer case is different in a chilling way: the company didn't even know who the person was. It's not fraud about what you're selling. It's fraud about who's doing the selling.
What Needs to Change
The biotech industry has no single federal requirement mandating background checks for executives. Screening varies by state, by role, by company policy. The SEC requires disclosure and internal controls, but it doesn't prescribe how companies should vet their hires. The FDA requires that staff have proper education and training for their roles, but verifying that is largely left to the company.
This patchwork approach clearly isn't enough.
Governance experts will likely push for several reforms: mandatory third-party credential verification for C-suite hires at public companies, alias and adverse-media screening as standard practice, and direct institutional verification of medical degrees and licenses (not just accepting what a candidate hands you).
Boards, venture funds, and pharma partners may also start demanding visible proof of vetting before signing deals or investing. "Trust but verify" only works if you actually verify.
The Bigger Picture
This story is bizarre, almost cinematic. A fugitive on a sailboat, a fake identity, a corner office in biotech. It reads like a Netflix limited series, and someone is probably already pitching it.
But beneath the sensational details sits a serious structural problem. Biotech runs on trust: trust that trials are run honestly, that data is real, that the people making life-or-death decisions about drug safety are who they say they are. When that trust breaks down, patients, investors, and the entire regulatory system bear the cost.
Immix Biopharma says there's no material impact on its business. Maybe that's true in a narrow, technical sense. But the material impact on the industry's credibility? That's a different calculation entirely.
Clinical & Regulatory
5 min read
Two Minutes to Decide If You Need Wegovy
Former LifeMD employees allege clinicians had just two minutes per patient to prescribe powerful GLP-1 weight-loss drugs. The STAT News investigation puts Novo Nordisk's entire telehealth strategy under a harsh spotlight.
